June 2026 Research Update

This month added an early signal that simple-looking changes on a routine blood smear might reflect deeper genetic complexity in splenic marginal zone lymphoma and related slow-growing B-cell cancers. In a small pilot group, patients whose blood cells showed more of these abnormalities also tended to have more chromosomal changes on genetic testing. If confirmed, this could offer a low-tech way to flag when a lymphoma looks more genetically "unstable." [1]

Researchers focused on two microscope findings called nucleoplasmic bridges and nuclear buds, which can be seen in cells on routine blood smears, and combined them into a Cytological Instability Score (a score based on what cells look like under the microscope). These features strongly tracked with measures of genomic instability and with more complex chromosome patterns. The study was small and exploratory, so it mainly shows that the idea is plausible rather than proving it is ready for routine use. [1]

For patients, this work mainly adds understanding of why some indolent lymphomas may behave more unpredictably than others, by linking cell appearance to genetic complexity. It does not establish a new test that people should expect in care right now, because the findings come from a small pilot study and need confirmation in larger groups. The helpful part is the clear direction of the signal: more abnormal-looking nuclei on a smear matched more chromosomal disruption, which could matter later if it proves useful for tracking disease biology over time. [1]

This month, the human evidence outside of larger studies came from case reports showing how varied the SMZL journey can be in real life. The reports described unusual presentations, possible overlaps with immune conditions, and a related lymphoma that can mimic SMZL. Together, they reinforce that SMZL is not always a straightforward picture of "big spleen and mild symptoms" and that different underlying problems can coexist. [2] [3] [4]

One case described a person with SMZL whose autopsy found multiple additional conditions, including autoimmune diseases and transthyretin amyloidosis (a protein buildup that can affect organs like the heart). The report connected the rapid decline to the amyloidosis rather than lymphoma alone, underscoring that in older adults, new organ problems may sometimes have more than one cause. Because this is one person, it cannot show how common this overlap is. [2]

Another report described SMZL presenting with a wandering spleen, meaning the spleen had moved from its usual position in the abdomen. The spleen was removed, and SMZL was diagnosed using flow cytometry (a lab test that characterizes blood cells). This case matters because it shows how a rare anatomic problem can be the first reason someone is evaluated, with SMZL discovered in the workup. [3]

Two additional cases focused on splenic diffuse red pulp small B-cell lymphoma (SDRPL), which can look similar to SMZL and may be mistaken for it. The report emphasized that a combination of blood smear review, flow cytometry patterns, and bone marrow findings supported SDRPL without needing splenectomy for diagnosis. In these two people, rituximab-based treatment was followed by major improvement, including complete remission in one case and quick shrinkage of spleen-related findings in the other. [4]

For patients and caregivers, these reports mainly matter as reminders about uncertainty and individual variation, rather than as evidence that care should change. They show that SMZL can appear in unusual ways (like a wandering spleen) and can also coexist with other conditions that affect the kidneys, nerves, lungs, or heart, which may shape symptoms and outcomes. They also show that some people first labeled as SMZL may later fit a closely related lymphoma (SDRPL) when more testing is reviewed, and that rituximab-based approaches were followed by improvement in the reported SDRPL cases. What remains uncertain is how often any of these situations occur, because case reports cannot estimate frequency or predict what will happen for others. [2] [3] [4]